Stock Analysis
Neurocrine Biosciences IncNBIX
P/E 19.55×· 5Y range 15.95–843.04×· bottom 6% of history
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy36 analystsP/E 19.6× sits at the 6th percentile of its 5.0513347022587265-year history.
Cash covers 84% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Growth95
- Financial Health88
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 6.0 — safe-zone balance sheet
- ✓ROE 19.1% — efficient capital deployment
- ✓Revenue CAGR 26.0% — durable top-line growth
- ✓Interest coverage 90.3× — debt well covered
What's happening with NBIX
Profile
Strong growth, financial health, profitability and valuation.
How is each axis scored?
- Valuation77/100 · Strong
- P/E vs own history (6th pct)25/25
- FCF yield (6.3%)20/25
- P/S (4.1x)20/25
- EV/EBIT (17.4x)12/25
- Growth95/100 · Strong
- Revenue CAGR (26.0%)25/25
- Net income CAGR (52.0%)25/25
- EPS CAGR 5Y (50.3%)25/25
- Fwd implied growth (25.5%)20/25
- Profitability85/100 · Strong
- ROIC (16.7%)20/25
- ROE (19.1%)20/25
- Net margin (20.9%)25/25
- Operating margin (23.6%)20/25
- Financial Health88/100 · Strong
- Altman Z (5.98)25/25
- Current ratio (1.87)18/25
- Interest coverage (90.3x)25/25
- Net cash / debt (D/A 1%)20/25
- Quality67/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-2.42)20/25
- FCF conversion (123%)25/25
- Margin stability (σ 379.4%)0/25
- Moat63/100 · Moderate
- ROIC >12% years (6/8 yrs)20/25
- Median gross margin (98.4%)25/25
- FCF-positive years (8/10 yrs)18/25
- Worst-year net margin (worst -940.6%)0/25
Risk Flags
- ⚠SBC 7.0% of revenue — real dilution cost
- ⚠2 loss-making years in recent history
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Show more
Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Headquarters: SAN DIEGO, CA · Employees: 2,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
77B+P/E (TTM)19.6xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 15.9x–843.0x · 6th pct
P/FCF15.9xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.3%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.0%–6.4% · highest in history
P/S (TTM)4.09xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 3.7x–9.7x · lowest in history
EV/EBIT17.4xB
Grade B: FairEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 16.6x–22.3x · 15th pct
EV/Sales4.0xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.6xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.73xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.48A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
85AROIC16.7%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE19.1%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA14.7%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin20.9%A
Grade A: HighNet Income / Revenue
Operating Margin23.6%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin56.7%A
Grade A: PremiumGross Profit / Revenue
FCF Margin25.8%A
Grade A: HighFCF / Revenue
True FCF Margin18.8%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
95A+Revenue CAGR26.0%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR52.0%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)50.3%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth25.5%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+3.7%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income33.2%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue7.0%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
88AAltman Z-Score5.98A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.87xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.51xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage90.3xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment0.1yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.1xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.12xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.84xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
67BPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.42A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion123.4%A
Grade A: StrongFCF / Net Income
Margin Stability379.4%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.8%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.70xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Boyer David W. Filed | Boyer David W. | SellOpen market sale | -826 | |
ABERNETHY MATT Filed | ABERNETHY MATT | SellOpen market sale | -2311 | |
Delaet Ingrid Filed | Delaet Ingrid | Tax withholding | -2419 | |
Delaet Ingrid Filed | Delaet Ingrid | Grant / award | +4.5K | |
Boyer David W. Filed | Boyer David W. | Tax withholding | -1936 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Boyer David W. Filed | Boyer David W. | Grant / award | +3.6K | |
Onyia Jude Filed | Onyia Jude | Tax withholding | -1936 | |
Onyia Jude Filed | Onyia Jude | Grant / award | +3.6K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
63BROIC >12% Years6/8 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)98.4%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years8/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-940.6%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$6.94
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.84
Cash & short-term investments per share (Finnhub)
Book Value / Share$36.35
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$461.60M
Total debt obligations (short + long term)
Cash & Equiv.$389.80M
Cash and short-term investments
Net Debt$71.80M
Total Debt minus Cash. Negative = Net Cash position
Total Equity$3.69B
Shareholders' equity (book value)
Asset / Liability3.22xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$13.79B
Current Market Capitalization
Beta0.33B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Neurocrine Biosciences Inc (NBIX)
NBIX is down 0.91% at the last close. Neurocrine Biosciences Inc meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 5.98 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.42 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 26% annually, with net income growing about 52% per year — a strong growth profile.
- Neurocrine Biosciences Inc converts about 26% of revenue into free cash flow — strong cash generation.
- Takes ~0.1 years to repay net debt from free cash flow.
- Neurocrine Biosciences Inc posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 77/100, NBIX trades near the cheapest end of its own historical range (P/E 19.6).
See how NBIX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all NBIX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 13 | Regular | 136.17 | -3.68% | -2.27 |
| Oct 13 | After-hours | 135.13 | -4.41% | -2.78 |
| Sep 30 | Regular | 142.22 | +2.80% | 2.18 |
Frequently Asked Questions about NBIX
What is the current Neurocrine Biosciences Inc (NBIX) stock price?
NBIX is trading at $135.71 at the last market close, down 0.91% on the session. PreMarketPrice tracks NBIX pre-market, intraday and after-hours prices.
Is NBIX stock a buy right now?
PreMarketPrice's quantitative model rates Neurocrine Biosciences Inc's financial health at 88/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is NBIX stock overvalued?
Neurocrine Biosciences Inc trades at a trailing P/E of 19.6 and our valuation score rates it 77/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Neurocrine Biosciences Inc report earnings?
No confirmed earnings date is currently scheduled for NBIX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Neurocrine Biosciences Inc operate in?
Neurocrine Biosciences Inc operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Neurocrine Biosciences Inc do?
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders.
About Neurocrine Biosciences Inc (NBIX) Stock
Neurocrine Biosciences Inc (NBIX) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Neurocrine Biosciences Inc is trading at $135.71, down 0.91% on the day with a market capitalization of $13.8 billion. The financial health score for NBIX is 88/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for NBIX stock.
NBIX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Neurocrine Biosciences Inc (NBIX) across multiple dimensions:
- Pre-market price & movement: Real-time NBIX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for NBIX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Neurocrine Biosciences Inc across multiple reporting periods.
- Financial health score: A composite score of 88/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for NBIX.
- Sector peers: Compare NBIX against 5 other healthcare stocks on key financial metrics.
Is NBIX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Neurocrine Biosciences Inc (NBIX) as an investment. The financial health score of 88/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Neurocrine Biosciences Inc (NBIX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.